Entera Bio (ENTX) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Surrozen (SRZN) has outperformed Entera Bio (ENTX) over the past year, gaining 115.6% versus a gain of 30.6%. Over five years, ENTX leads with a -3.6% price change compared with -79.0% for SRZN. Surrozen is the larger company by market cap ($596.4 million vs $575.5 million), about 1.0 times the size.
Surrozen converts more of its revenue into profit, with a net margin of -6960.8% versus -27235.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | SRZN |
|---|---|---|
| Share price | $3.31 | $28.46 |
| Market cap | $575.53M | $596.40M |
| 1-day change | +0.76% | -7.21% |
| YTD return | +70.36% | +25.93% |
| 1-year return | +30.63% | +115.61% |
| 5-year return | -3.64% | -78.97% |
| EPS (TTM) | $-0.40 | $-41.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $42.00K | $3.48M |
| Revenue growth (YoY) | -76.80% | -67.37% |
| Net income (latest FY) | $-11.44M | $-242.03M |
| Gross margin | 0.00% | — |
| Operating margin | -27450.00% | -1210.58% |
| Net margin | -27235.71% | -6960.77% |
| 52-week high | $4.20 | $37.83 |
| 52-week low | $0.91 | $12.79 |
| Distance from 52-week high | -21.31% | -24.77% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +195.01% | +123.12% |
| Average volume | 438.35K | 537.16K |
| Shares outstanding | 174.14M | 20.96M |
| Employees | 27 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed ENTX by 85.0 percentage points over the past year.
- Surrozen is more profitable, keeping -6960.8 cents of every revenue dollar as net income versus -27235.7 cents for Entera Bio.
- Surrozen grew revenue faster in its latest fiscal year (-67.37% vs -76.80%).
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 27 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
ENTX vs SRZN FAQ
Which is bigger, Entera Bio or Surrozen?
Surrozen (SRZN) is larger, with a market capitalization of $596.40M compared with $575.53M for Entera Bio (ENTX).
Which stock has performed better over the past year, ENTX or SRZN?
SRZN returned +115.61% over the past 12 months, compared with +30.63% for ENTX (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.